Literature DB >> 11262092

Synthesis and Src kinase inhibitory activity of a series of 4-phenylamino-3-quinolinecarbonitriles.

D H Boschelli1, Y D Wang, F Ye, B Wu, N Zhang, M Dutia, D W Powell, A Wissner, K Arndt, J M Weber, F Boschelli.   

Abstract

Screening of a directed compound library in a yeast-based assay identified 4-[(2,4-dichlorophenyl)amino]-6,7-dimethoxy-3-quinolinecarbonitrile (2a) as a Src inhibitor. An enzymatic assay established that 2a was an ATP-competitive inhibitor of the kinase activity of Src. We present here SAR data for 2a which shows that the aniline group at C-4, the carbonitrile group at C-3, and the alkoxy groups at C-6 and C-7 of the quinoline are crucial for optimal activity. Increasing the size of the C-2 substituent of the aniline at C-4 of 2a from chloro to bromo to iodo resulted in a corresponding increase in Src inhibition. Furthermore, replacement of the 7-methoxy group of 2a with various 3-heteroalkylaminopropoxy groups provided increased inhibition of both Src enzymatic and cellular activity. Compound 25, which contains a 3-morpholinopropoxy group, had an IC(50) of 3.8 nM in the Src enzymatic assay and an IC(50) of 940 nM for the inhibition of Src-dependent cell proliferation.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11262092     DOI: 10.1021/jm000420z

Source DB:  PubMed          Journal:  J Med Chem        ISSN: 0022-2623            Impact factor:   7.446


  9 in total

Review 1.  Therapeutic Targeting of the Gas6/Axl Signaling Pathway in Cancer.

Authors:  Mai Tanaka; Dietmar W Siemann
Journal:  Int J Mol Sci       Date:  2021-09-15       Impact factor: 6.208

2.  Src inhibition ameliorates polycystic kidney disease.

Authors:  William E Sweeney; Rodo O von Vigier; Philip Frost; Ellis D Avner
Journal:  J Am Soc Nephrol       Date:  2008-04-02       Impact factor: 10.121

3.  Pro32Pro33 mutations in the integrin β3 PSI domain result in αIIbβ3 priming and enhanced adhesion: reversal of the hypercoagulability phenotype by the Src inhibitor SKI-606.

Authors:  Kendra H Oliver; Tammy Jessen; Emily L Crawford; Chang Y Chung; James S Sutcliffe; Ana M Carneiro
Journal:  Mol Pharmacol       Date:  2014-04-02       Impact factor: 4.436

4.  Structural and spectroscopic analysis of the kinase inhibitor bosutinib and an isomer of bosutinib binding to the Abl tyrosine kinase domain.

Authors:  Nicholas M Levinson; Steven G Boxer
Journal:  PLoS One       Date:  2012-04-06       Impact factor: 3.240

Review 5.  Advancements in the synthesis of fused tetracyclic quinoline derivatives.

Authors:  Ramadan A Mekheimer; Mariam A Al-Sheikh; Hanadi Y Medrasi; Kamal U Sadek
Journal:  RSC Adv       Date:  2020-05-27       Impact factor: 4.036

6.  Discovery of drug-resistant and drug-sensitizing mutations in the oncogenic PI3K isoform p110 alpha.

Authors:  Eli R Zunder; Zachary A Knight; Benjamin T Houseman; Beth Apsel; Kevan M Shokat
Journal:  Cancer Cell       Date:  2008-08-12       Impact factor: 31.743

7.  The role of SRC family kinases in prostate cancer.

Authors:  Oleg Tatarov; Joanne Edwards
Journal:  Transl Oncogenomics       Date:  2007-10-14

Review 8.  Secondary Resistant Mutations to Small Molecule Inhibitors in Cancer Cells.

Authors:  Abdulaziz B Hamid; Ruben C Petreaca
Journal:  Cancers (Basel)       Date:  2020-04-09       Impact factor: 6.639

9.  In Vitro Comparison of the Effects of Imatinib and Ponatinib on Chronic Myeloid Leukemia Progenitor/Stem Cell Features.

Authors:  Ignazia Tusa; Giulia Cheloni; Martina Poteti; Angela Silvano; Alessandro Tubita; Zoe Lombardi; Antonella Gozzini; Roberto Caporale; Barbara Scappini; Persio Dello Sbarba; Elisabetta Rovida
Journal:  Target Oncol       Date:  2020-10       Impact factor: 4.493

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.